Ryght AI delivers an intelligent software platform powered by "AI Site Twins," dynamic data models that replicate every clinical research site worldwide in real time. The system ingests historical performance, patient-demographic and operational data to help life-sciences sponsors and contract research organizations more accurately run trial-feasibility analyses, choose optimal sites, forecast enrollment and streamline site-activation workflows. Built with generative and agentic AI and certified as SOC Type 2 compliant, the platform enables secure, real-time collaboration among sponsors, CROs and research sites. By shortening the traditionally manual processes of site selection and patient recruitment, Ryght AI aims to reduce costly delays and speed new therapies to market. The company is positioning its technology as a foundational layer that integrates with broader enterprise systems used by pharmaceutical and biotech firms. Ryght AI’s go-to-market strategy includes partnerships with global technology and consulting leaders to scale adoption across the industry.

Total raised

$3M

Funding rounds

2

Latest round

Seed

Latest activity

Jun 2025